Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

FDA grants priority review to selpercatinib New Drug Application

3
SHARES

Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

FDA approves new uses for two drugs administered together for treatment of BRAF-positive anaplastic thyroid cancer

The US Food and Drug Administration (FDA) has granted priority review to the New Drug Application (NDA) for selpercatinib, for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The NDA is based on data from the LIBRETTO-001 Phase I/II trial in RET-altered lung and thyroid cancers.

“We are pleased the FDA granted priority review status for the NDA for selpercatinib. This represents an important step toward providing a new precision therapy for people living with certain RET-driven cancers,” said Anne White, President of Lilly Oncology, which developed the treatment. “Combined with the recent opening of our two Phase III selpercatinib clinical trials, we are thrilled with the positive momentum of this program and hope to deliver a practice-changing treatment to patients with RET-driven cancers as soon as possible.”

In previous regulatory actions, based on early data from the Phase I/II LIBRETTO-001 trial, the FDA granted selpercatinib Breakthrough Therapy Designation for treatment in people with:

  • Metastatic RET-fusion-positive NSCLC who require systemic therapy and have progressed following platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy
  • RET-mutant MTC who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment option
  • Advanced RET-fusion-positive thyroid cancer who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options.

In 2019, selpercatinib received Orphan Drug designation for the treatment of RET fusion-positive NSCLC and for the treatment of RET fusion-positive and RET-mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, MTC and locally advanced or metastatic follicular or papillary thyroid cancer.

The FDA has filed the NDA and set a Prescription Drug User Fee Act (PDUFA) date in the third quarter of this year.

Share via
Share via